Bilcare Research has launched a product to help check the menace of counterfeit drugs. The product has a label with a unique bar code made out of nanotechnology and fingerprinting.
Former President of India, Dr. APJ Abdul Kalam and Dr. John L. LaMattina (Senior Vice President, Pfizer Inc and President, Pfizer Global Research & Development inaugurated Bilcare Centre of Excellence. The Centre will have dedicated R&D sections for Packaging Research, Material Research, Analytical Research, Drug Sensitivity Studies and Package Design. Bilcare provides integrated packaging solutions across the entire spectrum of pharmaceutical value chain through five focused business activities – Research Services, Clinical Supplies, Design Lab, Research Academy and Packaging Materials.
The Centre is also equipped with Asia’s first integrated Flexo Printing machine and a State-of-the art pilot plant which was inaugurated by Dr. R Chidambaram, Principal Scientific Advisor to Government of India.
According to the World Health Organization (WHO) 10% of global medicines, worth $50Bn are counterfeit and $150Bn revenue loss due to compliance related issues. To combat this global crisis, Bilcare Research has developed a unique product which was also jointly launched by Dr. APJ Abdul Kalam & Dr. John L. LaMattina. This product will help the pharmaceutical industry in securing their brands, increasing every product’s warranty, traceability and secure the supply chain management apart from eradicating counterfeit and ensuring better healthcare compliance.
Accorcding to Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited, the company is emerging fast as a knowledge company with unique research capabilities to address critical challenges of the pharmaceutical Industry. With this product and the R&D center launch, the company can offer complete solution to our global customers on counterfeit and ensure better healthcare for tomorrow.
Out of major investments in nanotechnology research & development happening today, this is one of the first cost effective and useful solution for the common man offered by Bilcare. The product has a label with a unique bar code made out of nanotechnology and fingerprinting. The customer has to swipe the drug packet in the scanner or at select ATMs to verify the authenticity of the drug. The $100-million Bilcare got a patent for the product in 22 months. The labels will be produced at Singapore. Manufacturing is slated to begin from the first quarter of the next calendar year and the commercial launch will be in June or July.
Bilcare operates state-of-the art manufacturing facilities in India, Singapore, US & UK and has regional offices in Brazil, Germany, China & Australia which caters to global clients including J&J, Merck, GSK, Sanofi, Pfizer, Novartis, Wyeth, Ranbaxy, Dr. Reddy to name few.